Seek Returns

ALNY vs. RVTY: Alnylam Pharmaceuticals vs. Revvity Stock Comparison

How do Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
Profile ItemALNYRVTY
NameAlnylam Pharmaceuticals, Inc.Revvity Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization20.89 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2004February 21, 1973
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ALNY
RVTY
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Total Return (1Y)-64.57%76.75%
Total Return (3Y, Annualized)-1.58%24.22%
Total Return (5Y, Annualized)-3.13%-1.48%

Risk Profile

Drawdown History

ALNY
RVTY
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Volatility (1Y, Annualized)54.08%40.22%
Beta (5Y)0.451.07
Max Drawdown (5Y)-68.25%-59.01%
Avg. Volume (3M)1.90M1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ALNY and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Sharpe Ratio (1Y)-1.271.80
Sortino Ratio (1Y)-1.452.90

Profitability

ROE (TTM)

Alnylam Pharmaceuticals (ALNY) at 138.07% clears its industry range for ROE, a sharper capital-efficiency signal than Revvity (RVTY) at 3.45%, which is closer to a typical peer reading.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY
138.07%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY
52.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max
83.12%
ALNY
23.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
ROE (TTM)138.07%3.45%
ROA (TTM)9.51%2.54%
Net Margin (TTM)52.85%8.61%
Operating Margin (TTM)23.72%17.06%
Gross Margin (TTM)77.28%55.91%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Revvity (RVTY) at 3.67% is closer to the peer norm — faster top-line expansion for ALNY.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Revenue Growth (YoY)65.19%3.67%
Revenue Growth (3Y CAGR)52.98%-4.82%
EPS Growth (YoY)---5.91%
EPS Growth (3Y CAGR)---23.26%

Financial Strength

Current Ratio (MRQ)

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max
25.13
Q3
12.13
Median
5.52
ALNY
2.48
Q1
2.47
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revvity (RVTY) at 0.38 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
1.42
ALNY
0.83
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Current Ratio (MRQ)2.482.65
Debt / Equity (MRQ)0.830.38
Net Debt / EBITDA-0.572.43

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
Dividend Yield (TTM)0.00%0.19%
Dividend Payout Ratio (TTM)0.00%13.40%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Revvity (RVTY) at 68.94 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
ALNY
7.88
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max
58.18
Q3
25.77
Median
7.30
ALNY
4.17
Q1
3.01
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max
13.53
Q3
6.54
ALNY
5.79
Median
3.25
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Revvity (RVTY)
MetricALNYRVTY
P/E Ratio (TTM)7.8868.94
P/S Ratio (TTM)4.175.88
P/B Ratio (MRQ)5.792.39
Free Cash Flow Yield (TTM)1.57%3.62%